168 related articles for article (PubMed ID: 32940862)
1. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
2. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
3. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144.
Pozios I; Hering NA; Guenzler E; Arndt M; Elezkurtaj S; Knösel T; Bruns CJ; Margonis GA; Beyer K; Seeliger H
J Cancer Res Clin Oncol; 2023 Jan; 149(1):271-280. PubMed ID: 36495330
[TBL] [Abstract][Full Text] [Related]
4. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
5. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
7. Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.
Pozios I; Knösel T; Zhao Y; Assmann G; Pozios I; Müller MH; Bruns CJ; Kreis ME; Seeliger H
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1887-1897. PubMed ID: 30046904
[TBL] [Abstract][Full Text] [Related]
8. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective action of raloxifene against hypoxia-induced damage in mouse hippocampal cells depends on ERα but not ERβ or GPR30 signalling.
Rzemieniec J; Litwa E; Wnuk A; Lason W; Gołas A; Krzeptowski W; Kajta M
J Steroid Biochem Mol Biol; 2015 Feb; 146():26-37. PubMed ID: 24846829
[TBL] [Abstract][Full Text] [Related]
11. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
12. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE
Luo P; Shi W; Wang Y; Ma H; Liu T; Yan D; Huo S; Guo J; Wang M; Li C; Lin J; Zhang C; Li S; Lv J; Lin L
Life Sci; 2020 Nov; 261():118304. PubMed ID: 32828944
[TBL] [Abstract][Full Text] [Related]
14. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
[TBL] [Abstract][Full Text] [Related]
15. Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells.
Wang HC; Yeh HH; Huang WL; Lin CC; Su WP; Chen HH; Lai WW; Su WC
Mol Endocrinol; 2011 Jul; 25(7):1145-58. PubMed ID: 21546410
[TBL] [Abstract][Full Text] [Related]
16. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells.
Tu Z; Ma Y; Tian J; Li H; Akers W; Achilefu S; Gu Y
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1091-103. PubMed ID: 22398780
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IL-6/STAT3 signaling in human cancer cells using Evista.
Shi W; Yan D; Zhao C; Xiao M; Wang Y; Ma H; Liu T; Qin H; Zhang C; Li C; Lin J; Li S; Lv J; Lin L
Biochem Biophys Res Commun; 2017 Sep; 491(1):159-165. PubMed ID: 28711499
[TBL] [Abstract][Full Text] [Related]
19. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
20. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]